June is almost over and China’s National Medical Products Administration (NMPA) is gearing up to approve more novel drugs to help build up a pool of candidates for the next round of price negotiations due to take place late in the year.
The latest batch of candidates includes savolitinib from HUTCHMED (China) Limited (formerly Chi-Med). With the recent approval of the...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

